BPI Contributor

November 15, 2023

20 Min View
Expansion of Samsung Biologics' Business Into Late Discovery/Early Development

Date: Nov 15, 2023

Duration: 20 Min

This webcast features: Derrick Katayama, Lead Scientist, Formulation Development, Samsung Biologics.

As the global biopharmaceutical market rapidly expands, the increasing demand for drug development underscores the significance of effective assessment tools for selecting biologic compounds with adequate stability and developability. In response to these critical requirements, Samsung Biologics offers cutting-edge technology and an innovative approach from the early development stages with its advanced development platform, resulting in streamlined development time and costs.

In this webinar, Samsung Biologics explores its proprietary development platforms, DEVELOPICK™ and S-CHOsient™, through real-life case studies. The webinar will demonstrate how DEVELOPICK™, a developability assessment platform, has been meticulously structured based on an evaluation procedure for candidate selection before proceeding into development, by evaluating a variety of characteristics (including physicochemical). Also, it will show how S-CHOsient™, a transient expression platform, helps efficiently produce adequate protein amounts, enabling clients to evaluate candidate characteristics during preliminary studies.

Key Takeaways:

  • Learn the value of performing a developability assessment at the late discovery/early development stage.

  • Understand the rationale behind using DEVELOPICK™ in the workflow process.

  • Gain insight of the benefits involved in the S-CHOsient™ platform.

You May Also Like